title: [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
abstract: The carcinoembryonic antigen glypican-3 (GPC3) is an ideal target of tumor antigen-specific immunotherapy against hepatocellular carcinoma (HCC), because it is overexpressed specifically in HCC. We have reported that a GPC3-derived peptide vaccination was well-tolerated, and immune responses and antitumor efficacy were noted in a phase I trial for HCC patients. We have begun a phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for HCC patients, and a pilot study of liver biopsies performed before and after GPC3 peptide vaccination for advanced HCC to determine whether tumor-infiltrating lymphocytes are indeed GPC3 peptide-specific CTLs. Furthermore, we are initiating clinical trials of a GPC3-derived peptide vaccine for patients with hepatoblastoma or ovarian clear cell carcinoma.
authors.affiliation: Division of Cancer Immunotherapy, Research Center for Innovative Oncology, National Cancer Center Hospital East.
authors.forename: Yu
authors.initials: Y
authors.lastname: Sawada
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Nakatsura
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D053673:Glypicans / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D053673:Glypicans